Evidence map›Paper›PMID 42438056›Full record

Trial reportGut microbes2026

Berengère Benoit, Pierre Letourneau, Vincent Verdier, Angélique Viney, Cécile Barnel, Karim Chikh, Oriane Vitalis, Audrey Jalabert, Sandra Wagner, Manolo Laiola and 19 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Gut microbes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Berengère BenoitUniversité Lyon1, INSERM, INRAE, CarMeN, Pierre Bénite, France.
Pierre LetourneauUniversité Lyon1, INSERM, INRAE, CarMeN, Pierre Bénite, France.
Vincent VerdierDepartement of Nephrology, University Hospital of Reims, Reims, France.
Angélique VineyDepartment of Nephrology and Nutrition, Hospices Civils de Lyon, Hôpital Lyon-Sud, Pierre-Bénite, France.
Cécile BarnelDepartment of Nephrology and Nutrition, Hospices Civils de Lyon, Hôpital Lyon-Sud, Pierre-Bénite, France.
Karim ChikhUniversité Lyon1, INSERM, INRAE, CarMeN, Pierre Bénite, France.ORCID 0000-0002-1217-4193
Oriane VitalisLaboratoire de Biochimie, Hospices Civils de Lyon, Hôpital Lyon-Sud, Pierre-Bénite, France.ORCID 0009-0009-4069-0943
Audrey JalabertUniversité Lyon1, INSERM, INRAE, CarMeN, Pierre Bénite, France.
Sandra WagnerUniversité de Lorraine, INSERM CIC 1433, Nancy CHRU, Inserm U1116, FCRIN INI-CRCT, Nancy, France.
Manolo LaiolaUniversité Paris-Saclay, INRAE, MGP, Jouy-en-Josas, France.
Natalia Alencar-De-PinhoCentre for Research in Epidemiology and Population Health (CESP), Paris-Saclay University, Versailles Saint-Quentin University, INSERM UMRS 1018, Clinical Epidemiology Team, Villejuif, France.
Florence ThirionUniversité Paris-Saclay, INRAE, MGP, Jouy-en-Josas, France.ORCID 0000-0002-2310-5548
Stéphanie ChanonUniversité Lyon1, INSERM, INRAE, CarMeN, Pierre Bénite, France.
Aurélie Vieille-MarchisetUniversité Lyon1, INSERM, INRAE, CarMeN, Pierre Bénite, France.
Sarah TeixeiraService de Biostatistique, Hospices Civils de Lyon, Pierre-Bénite, France.
Fabien SubtilService de Biostatistique, Hospices Civils de Lyon, Pierre-Bénite, France.
Sylvie BinService Recherche et Épidémiologie Cliniques, Pôle de Santé Publique, Hospices Civils de Lyon, France.
Alice BeauUniversité Lyon1, INSERM, INRAE, CarMeN, Pierre Bénite, France.
Claudie PinteurUniversité Lyon1, INSERM, INRAE, CarMeN, Pierre Bénite, France.
Ziad A MassyCentre for Research in Epidemiology and Population Health (CESP), Paris-Saclay University, Versailles Saint-Quentin University, INSERM UMRS 1018, Clinical Epidemiology Team, Villejuif, France.
Pamela DuguesDepartment of Pharmacology and Toxicology, Raymond Poincaré Hospital, AP-HP, Garches; Centre for Research in Epidemiology and Population Health (CESP), Team MOODS, Inserm UMRS 1018, UVSQ-Paris-Saclay University, Montigny-le-Bretonneux, France.
Jean-Claude AlvarezDepartment of Pharmacology and Toxicology, Raymond Poincaré Hospital, AP-HP, Garches; Centre for Research in Epidemiology and Population Health (CESP), Team MOODS, Inserm UMRS 1018, UVSQ-Paris-Saclay University, Montigny-le-Bretonneux, France.
Amine LarabiDepartment of Pharmacology and Toxicology, Raymond Poincaré Hospital, AP-HP, Garches; Centre for Research in Epidemiology and Population Health (CESP), Team MOODS, Inserm UMRS 1018, UVSQ-Paris-Saclay University, Montigny-le-Bretonneux, France.
Griet GlorieuxNephrology Unit, Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent, Belgium.
Filipe De VadderInstitute of Functional Genomics of Lyon, ENS Lyon, CNRS, Université Claude Bernard Lyon 1, UMR5242, Lyon, France.
Christophe SoulageUniversité Lyon1, INSERM, INRAE, CarMeN, Pierre Bénite, France.
François LeulierInstitute of Functional Genomics of Lyon, ENS Lyon, CNRS, Université Claude Bernard Lyon 1, UMR5242, Lyon, France.
Hubert VidalUniversité Lyon1, INSERM, INRAE, CarMeN, Pierre Bénite, France.
Laetitia KoppeUniversité Lyon1, INSERM, INRAE, CarMeN, Pierre Bénite, France.ORCID 0000-0002-5076-2420

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Low-protein diets (LPD) are recommended in chronic kidney disease (CKD) to reduce disease progression. However, their clinical efficacy and safety are debated due to the risk of protein-energy wasting. A deeper mechanistic understanding is therefore required. Herein, the metabolic effects of LPD in both murine models and a randomized controlled trial in nondiabetic CKD patients were investigated, focusing on glucose homeostasis, plasmatic uremic toxin (UTs) levels, gut microbiota remodeling, and endocrine adaptations. In both experimental and clinical settings, LPD improved glucose tolerance and significantly decreased circulating levels of gut-derived UTs while reducing body weight (-33% weight gain in mice and a decrease in body mass index of ~-0.5 kg/m

Indexed as

Diet, Protein-RestrictedFibroblast Growth FactorsLactiplantibacillus plantarumProbioticsRenal Insufficiency, ChronicAnimalsFemaleGastrointestinal MicrobiomeHumansMaleMiceMice, Inbred C57BLMiddle AgedStress, PhysiologicalUremic Toxinsfibroblast growth factor 21Fibroblast Growth FactorsUremic Toxinschronic kidney diseasegut microbiotalow-protein dietProbioticsuremic toxins

Identifiers

PMID42438056
PMCPMC13367091

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.